XORTX Announces Pricing of US$1.1 Million Registered Direct Offering
(TSX-V:XRTX),(NASDAQ:XRTX),(Boerse Frankfurt – Freiverkehr:ANUA.F), CALGARY, Alberta, Oct. 21, 2025 (GLOBE NEWSWIRE) — XORTX Therapeutics Inc. (“XORTX” or the “Company“) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that it has entered into a securities purchase agreement […]